ICMR Initiates First-In-Human Trials for Zika, Flu, and Blood Cancer Vaccines

Introduction to ICMR's Vaccine Initiatives

ICMR is advancing its endeavors in clinical research by launching first-in-human trials for multiple vaccines. This effort includes a Zika vaccine, a seasonal flu vaccine, and treatments for blood cancer, namely multiple myeloma and chronic lymphocytic leukemia.

Details of the Clinical Trials

First-in-human trials are crucial as they test new treatments after successful laboratory and animal studies. The ICMR has partnered with Indian Immunologicals for the Zika vaccine and Mynvax for the flu vaccine, alongside Aurigene Oncology for blood cancer therapies.

• Zika Vaccine: Collaborative development with Indian Immunologicals.
• Flu Vaccine: Trial organized with Mynvax, focusing on seasonal flu.
• Blood Cancer Treatments: Partnership with Aurigene Oncology for multiple myeloma.

Infrastructure and Support

The ICMR's network comprises four main institutions across India to facilitate these trials, including key medical centers in Mumbai, Navi Mumbai, Tamil Nadu, and Chandigarh. This structure is essential for building clinical trial capabilities within the country.

Impact on Healthcare Development

Dr. Rajiv Bahl highlighted the significance of this initiative, emphasizing the importance of public-private partnerships in driving clinical research and fostering the development of indigenous healthcare solutions.